{"disease":{"id":"metastatic-cholangiocarcinoma","name":"metastatic cholangiocarcinoma"},"drugs":{"marketed":[{"drug_id":"pf-07220060-pf-07104091-combination-dose-escalation","indication_name":"Biomarker-eligible patients with unresectable or metastatic cholangiocarcinoma","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"PF-07220060 + PF-07104091 combination dose escalation","generic_name":"pf-07220060-pf-07104091-combination-dose-escalation","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"infigratinib","indication_name":"Unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Truseltiq","generic_name":"INFIGRATINIB","company_name":"Helsinn Hlthcare","drug_phase":"marketed","molecular_target":"Fibroblast growth factor receptor 2","drug_class":"","quality_score":40,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT07454486","title":"TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary Tract Cancer: a Real- World Cohort","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":300,"lead_sponsor_name":"Aarhus University Hospital","has_results":false},{"nct_id":"NCT02989857","title":"Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":true},{"nct_id":"NCT03656536","title":"A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":167,"lead_sponsor_name":"Incyte Corporation","has_results":false},{"nct_id":"NCT03665285","title":"A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":109,"lead_sponsor_name":"NextCure, Inc.","has_results":true},{"nct_id":"NCT04068194","title":"Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":103,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03043547","title":"Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT04801095","title":"A Phase I Study of WM-S1-030 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Wellmarker Bio","has_results":false},{"nct_id":"NCT03201458","title":"Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03849469","title":"A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"Xencor, Inc.","has_results":false},{"nct_id":"NCT05286814","title":"PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT06302621","title":"Pemigatinib + Afatinib in Advanced Refractory Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT05346484","title":"A Study of CF33-hNIS (VAXINIA), an Oncolytic Virus, as Monotherapy or in Combination With Pembrolizumab in Adults With Metastatic or Advanced Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":66,"lead_sponsor_name":"Imugene Limited","has_results":false},{"nct_id":"NCT03368963","title":"TAS102 in Combination With NAL-IRI in Advanced GI Cancers","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":64,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT02495896","title":"Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":61,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT07043387","title":"Streamlining Radioembolization for CCC and Metastatic Liver Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT04941287","title":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03257761","title":"Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":55,"lead_sponsor_name":"University of Southern California","has_results":false},{"nct_id":"NCT04383210","title":"Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":54,"lead_sponsor_name":"Elevation Oncology","has_results":true},{"nct_id":"NCT05872867","title":"Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Wellmarker Bio","has_results":false},{"nct_id":"NCT06501625","title":"Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":52,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03250273","title":"A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","has_results":true},{"nct_id":"NCT04175912","title":"Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":40,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT02990481","title":"A Phase 1 Study Evaluating the Safety of TRK-950 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Toray Industries, Inc","has_results":false},{"nct_id":"NCT03829436","title":"TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Tempest Therapeutics","has_results":false},{"nct_id":"NCT05655949","title":"Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT00286013","title":"Feasibility of Radiotherapy and Concomitant Gemcitabine and Oxaliplatin in Locally Advanced Pancreatic Cancer and Distal Cholangiocarcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT03027284","title":"A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT01825603","title":"ADH-1, Gemcitabine Hydrochloride & Cisplatin in Treating Metastatic Pancreatic or Biliary Tract Cancer","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"University of Nebraska","has_results":false},{"nct_id":"NCT06058663","title":"Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":16,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT06290856","title":"Clinical Utility of Selected Circulating Tumor DNA Assays in Patients With Advanced Malignancy","phase":"","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT06178588","title":"Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":15,"lead_sponsor_name":"University of Kansas Medical Center","has_results":false},{"nct_id":"NCT05285358","title":"Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"City of Hope Medical Center","has_results":false},{"nct_id":"NCT04088188","title":"Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT06420349","title":"NXP800 for the Treatment of Patients With Advanced or Metastatic Cholangiocarcinoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT04708067","title":"Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02757391","title":"CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04511793","title":"Hepatic Artery Infusion (HAI) Program at Duke University","phase":"NA","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Michael Lidsky, M.D.","has_results":false}],"total":38},"guidelines":[],"source":"Drug Landscape verified database"}